Delmar Pharma (DMPI) 1.2300 $DMPI
DelMar Pharmaceuticals VAL-083 Clinical Trial in GBM Demonstrates Continued and Promising Progress at AACR
PR Newswire - Wed Apr 09, 10:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioblastoma Multiforme" during the Early Phase Clinical Trials 2 Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
DelMar Pharmaceuticals Presents Promising Pre-clinical Data with VAL-083 in Lung Cancer
PR Newswire - Mon Apr 07, 9:30AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
DelMar Pharmaceuticals to Present Two Abstracts at American Association of Cancer Research (AACR) Annual Meeting
PR Newswire - Wed Apr 02, 12:20PM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" today announced that the Company would present two abstracts at the 105th Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 5-9, 2014, in San Diego.
DelMar Pharmaceuticals Gives Quarterly Shareholder Update and Announces Investor Conference Call
PR Newswire - Thu Mar 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call.
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial
PR Newswire - Thu Mar 06, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals recent update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
DelMar Pharmaceuticals to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Tue Mar 04, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26th Annual ROTH Capital Conference.
DelMar Pharmaceuticals Provides Update on VAL-083 Glioblastoma Clinical Trial
PR Newswire - Wed Feb 26, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
Many Business Leaders Only Play The Game While Others Change The Game
PR Newswire - Tue Feb 11, 7:30AM CST
America's PremierExperts® recently showcased a group of the country's leading businesspeople from various industries who are not just "playing the game" but they are changing it.
SeeThruEquity Initiates Research Coverage on DelMar Pharmaceuticals, Inc.
PR Newswire - Mon Jan 13, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
PR Newswire - Mon Dec 09, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.
NYSE, OTC and Nasdaq Companies Webcast to Online Investors: December 5th at RetailInvestorConferences.com
PR Newswire - Tue Dec 03, 6:30AM CST
PR Newswire, BetterInvesting, and MUNCmedia today announced the agenda of the upcoming RetailInvestorConferences.com, the monthly online investor conference series. Individual investors, institutional investors and analysts are invited.
DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th
PR Newswire - Mon Dec 02, 3:11PM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
PR Newswire - Fri Nov 22, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the first four cohorts of the VAL-083 trial has been completed with no significant adverse events or dose limiting toxicity (DLT) observed. Twenty five percent of patients evaluated in Cohorts 1-3 exhibited stable disease or tumor-regression and improved disease symptoms. Evaluation and clinical observations of Cohort 4 is ongoing.
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
PR Newswire - Thu Nov 14, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21st through 24th in San Francisco. Glioblastoma is the most common and aggressive form of brain cancer, and new therapies are greatly needed.
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
PR Newswire - Mon Nov 11, 7:00AM CST
Dear Shareholders and Friends of DelMar Pharmaceuticals:
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
PR Newswire - Mon Oct 21, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced the presentation of data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. The data presented today, along with historical research by the U.S. National Cancer Institute (NCI), support the utility of VAL-083 as a potential new treatment for three chemotherapy resistant cancers: glioblastoma (GBM), chronic myelogenous leukemia (CML) and non-small cell lung cancer (NSCLC).
DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
PR Newswire Europe - Thu Sep 19, 7:01AM CDT
-- Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers
CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
PR Newswire - Wed Sep 11, 8:00AM CDT
CCG Investor Relations, a leading global investor relations and strategic communications consultancy, is pleased to announce the companies who will present their investment stories as part of the Life Sciences Virtual Investment Conference to be held on Thursday, September 12, 2013.
DelMar Pharmaceuticals VAL-083 Clinical Trial in GBM Demonstrates Continued and Promising Progress at AACR
PR Newswire - Wed Apr 09, 10:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced an update on its ongoing Phase I/II clinical trial with VAL-083 in the treatment of refractory glioblastoma multiforme (GBM). The company's new data are being presented in a poster entitled, "A Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioblastoma Multiforme" during the Early Phase Clinical Trials 2 Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. DelMar Pharmaceuticals Presents Promising Pre-clinical Data with VAL-083 in Lung Cancer
PR Newswire - Mon Apr 07, 9:30AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. DelMar Pharmaceuticals to Present Two Abstracts at American Association of Cancer Research (AACR) Annual Meeting
PR Newswire - Wed Apr 02, 12:20PM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"
today announced that the Company would present two abstracts at the 105th Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 5-9, 2014, in San Diego. DelMar Pharmaceuticals Gives Quarterly Shareholder Update and Announces Investor Conference Call
PR Newswire - Thu Mar 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
provided an update as of the quarter ended December 31, 2013 and a summary of progress toward the Company's goals for the year. DelMar also announced an investor conference call to take place today at 1 pm EDT. Details and log-in information will be posted on the website at www.delmarpharma.com in advance of the call. SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial
PR Newswire - Thu Mar 06, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The note is focuses on DelMar Pharmaceuticals recent update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM).
DelMar Pharmaceuticals to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Tue Mar 04, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26th Annual ROTH Capital Conference. DelMar Pharmaceuticals Provides Update on VAL-083 Glioblastoma Clinical Trial
PR Newswire - Wed Feb 26, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). Many Business Leaders Only Play The Game While Others Change The Game
PR Newswire - Tue Feb 11, 7:30AM CST
America's PremierExperts® recently showcased a group of the country's leading businesspeople from various industries who are not just "playing the game" but they are changing it.
SeeThruEquity Initiates Research Coverage on DelMar Pharmaceuticals, Inc.
PR Newswire - Mon Jan 13, 8:00AM CST
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
PR Newswire - Mon Dec 09, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.
NYSE, OTC and Nasdaq Companies Webcast to Online Investors: December 5th at RetailInvestorConferences.com
PR Newswire - Tue Dec 03, 6:30AM CST
PR Newswire, BetterInvesting, and MUNCmedia today announced the agenda of the upcoming RetailInvestorConferences.com, the monthly online investor conference series. Individual investors, institutional investors and analysts are invited.
DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com December 5th
PR Newswire - Mon Dec 02, 3:11PM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
PR Newswire - Fri Nov 22, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the first four cohorts of the VAL-083 trial has been completed with no significant adverse events or dose limiting toxicity (DLT) observed. Twenty five percent of patients evaluated in Cohorts 1-3 exhibited stable disease or tumor-regression and improved disease symptoms. Evaluation and clinical observations of Cohort 4 is ongoing. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
PR Newswire - Thu Nov 14, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21st through 24th in San Francisco. Glioblastoma is the most common and aggressive form of brain cancer, and new therapies are greatly needed. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
PR Newswire - Mon Nov 11, 7:00AM CST
Dear Shareholders and Friends of DelMar Pharmaceuticals:
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
PR Newswire - Mon Oct 21, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced the presentation of data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Annual Meeting. The data presented today, along with historical research by the U.S. National Cancer Institute (NCI), support the utility of VAL-083 as a potential new treatment for three chemotherapy resistant cancers: glioblastoma (GBM), chronic myelogenous leukemia (CML) and non-small cell lung cancer (NSCLC). DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
PR Newswire Europe - Thu Sep 19, 7:01AM CDT
-- Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers
CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
PR Newswire - Wed Sep 11, 8:00AM CDT
CCG Investor Relations, a leading global investor relations and strategic communications consultancy, is pleased to announce the companies who will present their investment stories as part of the Life Sciences Virtual Investment Conference to be held on Thursday, September 12, 2013.
